These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30268913)

  • 1. The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice.
    Suschak JJ; Bagley K; Six C; Shoemaker CJ; Kwilas S; Spik KW; Dupuy LC; Schmaljohn CS
    Antiviral Res; 2018 Nov; 159():113-121. PubMed ID: 30268913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice.
    Suschak JJ; Bagley K; Shoemaker CJ; Six C; Kwilas S; Dupuy LC; Schmaljohn CS
    J Infect Dis; 2018 Nov; 218(suppl_5):S519-S527. PubMed ID: 30053157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.
    Dupuy LC; Richards MJ; Livingston BD; Hannaman D; Schmaljohn CS
    J Immunol Res; 2018; 2018():8521060. PubMed ID: 29967804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.
    Dupuy LC; Richards MJ; Ellefsen B; Chau L; Luxembourg A; Hannaman D; Livingston BD; Schmaljohn CS
    Clin Vaccine Immunol; 2011 May; 18(5):707-16. PubMed ID: 21450977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.
    Braid LR; Hu WG; Davies JE; Nagata LP
    Stem Cells Transl Med; 2016 Aug; 5(8):1026-35. PubMed ID: 27334491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
    Tretyakova I; Tibbens A; Jokinen JD; Johnson DM; Lukashevich IS; Pushko P
    Vaccine; 2019 May; 37(25):3317-3325. PubMed ID: 31072736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Apr; 28(18):3143-51. PubMed ID: 20193792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.
    Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS
    Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates.
    Dupuy LC; Richards MJ; Reed DS; Schmaljohn CS
    Vaccine; 2010 Oct; 28(46):7345-50. PubMed ID: 20851089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product.
    Perkins SD; Williams AJ; O'Brien LM; Laws TR; Phillpotts RJ
    Viral Immunol; 2008 Dec; 21(4):451-7. PubMed ID: 19115934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Jan; 28(4):1031-40. PubMed ID: 19914193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.
    Henning L; Endt K; Steigerwald R; Anderson M; Volkmann A
    Front Immunol; 2020; 11():598847. PubMed ID: 33542715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus.
    Suschak JJ; Dupuy LC; Shoemaker CJ; Six C; Kwilas SA; Spik KW; Williams JA; Schmaljohn CS
    Mol Ther Methods Clin Dev; 2020 Jun; 17():810-821. PubMed ID: 32296729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.
    Gupta P; Sharma A; Spurgers KB; Bakken RR; Eccleston LT; Cohen JW; Honnold SP; Glass PJ; Maheshwari RK
    Vaccine; 2016 May; 34(25):2762-5. PubMed ID: 27129427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing multivalent immunogens for alphavirus vaccine optimization.
    Read CM; Plante K; Rafael G; Rossi SL; Braun W; Weaver SC; Schein CH
    Virology; 2021 Sep; 561():117-124. PubMed ID: 33823988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection.
    O'Brien L; Perkins S; Williams A; Eastaugh L; Phelps A; Wu J; Phillpotts R
    J Gen Virol; 2009 Apr; 90(Pt 4):874-882. PubMed ID: 19264673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.
    Samsa MM; Dupuy LC; Beard CW; Six CM; Schmaljohn CS; Mason PW; Geall AJ; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):850-865. PubMed ID: 30770173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination.
    Perkins SD; O'Brien LM; Phillpotts RJ
    Vaccine; 2006 Apr; 24(17):3440-5. PubMed ID: 16527377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV.
    Phillpotts RJ; Lescott TL; Jacobs SC
    Acta Virol; 2000 Oct; 44(5):233-9. PubMed ID: 11252667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.